Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions
Open Access
- 7 November 2022
- journal article
- research article
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 7 (2) , 164-176
Abstract
Short half-lives in circulation and poor transport across the blood–brain barrier limit the utility of cytokines and growth factors acting as receptor agonists. Here we show that surrogate receptor agonists with longer half-lives in circulation and enhanced transport rates across the blood–brain barrier can be generated by genetically inserting macrocyclic peptide pharmacophores into the structural loops of the fragment crystallizable (Fc) region of a human immunoglobulin. We used such ‘lasso-grafting’ approach, which preserves the expression levels of the Fc region and its affinity for the neonatal Fc receptor, to generate Fc-based protein scaffolds with macrocyclic peptides binding to the receptor tyrosine protein kinase Met. The Met agonists dimerized Met, inducing biological responses that were similar to those induced by its natural ligand. Moreover, lasso-grafting of the Fc region of the mouse anti-transferrin-receptor antibody with Met-binding macrocyclic peptides enhanced the accumulation of the resulting Met agonists in brain parenchyma in mice. Lasso-grafting may allow for designer protein therapeutics with enhanced stability and pharmacokinetics.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21fk0210087, JP19am0101090, JP19am0101075)
- MEXT | Japan Society for the Promotion of Science (20K06553, 21H01771, 19H03499, 21K18250)
This publication has 55 references indexed in Scilit:
- Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumor‐Targeting MiniproteinsAngewandte Chemie International Edition, 2012
- Functions of neurotrophins and growth factors in neurogenesis and brain repairCytometry Part A, 2012
- Integrin binding human antibody constant domains—Probing the C-terminal structural loops for grafting the RGD motifJournal of Biotechnology, 2011
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis TargetScience Translational Medicine, 2011
- Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safetyJournal of Translational Medicine, 2011
- MET signalling: principles and functions in development, organ regeneration and cancerNature Reviews Molecular Cell Biology, 2010
- Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”Blood, 2008
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouseBiotechnology and Bioengineering, 2008
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune diseaseInternational Immunology, 2006